Back to top

vaccines: Archive

Zacks Equity Research

MRNA Stock Jumps on CDC's Revised RSV Vaccine Recommendations

Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.

GSKNegative Net Change PFEPositive Net Change MRNAPositive Net Change

Zacks Equity Research

Moderna Stock Gains on Encouraging Flu Vaccine Data

MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.

GSKNegative Net Change MRNAPositive Net Change AGENPositive Net Change AMRNPositive Net Change